 |
Photo = Samsung Biologics |
[Alpha Biz= Kim Jisun] Samsung Biologics has expanded its global manufacturing network by securing its first production base in the United States.
The company announced on April 1 that it has completed the acquisition of a biopharmaceutical manufacturing facility in Rockville, Maryland, from GlaxoSmithKline (GSK) as of March 31 (local time). The acquisition was carried out through its U.S. subsidiary, Samsung Biologics America.
The Rockville facility has a total capacity of 60,000 liters for drug substance (DS) production and consists of two manufacturing buildings. It is equipped to support antibody drug production across a wide range of scales, from clinical-stage development to commercial manufacturing.
With this acquisition, Samsung Biologics’ total production capacity has increased from 785,000 liters to 845,000 liters. The company now operates a dual manufacturing system linking its Songdo facilities in Korea with the new U.S. site, enabling more stable and flexible supply to global clients.
The establishment of a North American production base is expected to enhance responsiveness to local customers and strengthen Samsung Biologics’ competitiveness in securing global contracts.
To ensure operational continuity, the company has retained approximately 500 employees from the existing facility. It also plans to pursue integrated operations between its Korea and U.S. sites to support stable supply of existing products while expanding new business opportunities.
Looking ahead, Samsung Biologics is considering additional investments to further expand production capacity and upgrade technology at the Rockville facility, in line with mid- to long-term demand and utilization trends.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
